

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NALOX-1 PHARMACEUTICALS, LLC,
Petitioner,

v.

ADAPT PHARMA LTD,
OPIANT PHARMACEUTICALS, INC.,
Patent Owners

IPR2019-00693
U.S. Patent No. 9,561,177

**PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,561,177
AS OBVIOUS OVER DAVIES**

Table of Contents

I.	INTRODUCTION.....	1
II.	IPR REQUIREMENTS UNDER 37 C.F.R. § 42.104	2
A.	Grounds for Standing Under 37 C.F.R. § 42.104(a).....	2
B.	Identification of Challenge Under 37 C.F.R. § 42.104(b)	3
1.	Statutory Grounds of Challenge.....	3
2.	Statement of Non-Redundancy	4
3.	Relief Requested	6
C.	Mandatory Notices Under 37 C.F.R. § 42.8	7
1.	Real Party-in-Interest Under 37 C.F.R. § 42.8(b)(1).....	7
2.	Related Matters Under 37 C.F.R. § 42.8(b)(2)	7
3.	Identification of Lead and Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3) 8	
4.	Service Information Under 37 C.F.R. § 42.8(b)(4).....	9
III.	LEVEL OF ORDINARY SKILL IN THE ART.....	9
IV.	OVERVIEW OF THE '177 PATENT	11
A.	Summary of the Specification	11
B.	Summary of the Claims.....	12
C.	Summary of the Relevant Portions of the File History	12
D.	The '177 Patent Lacks Priority to the Filing Date of the '379 Provisional	14
V.	BACKGROUND AND OVERVIEW OF TECHNOLOGY.....	16
A.	A POSA Would Have Been Motivated to Develop Improved Intranasal Naloxone Formulations to Combat the Opioid Epidemic.....	16
B.	A POSA Would Have Had the Know-How to Readily Develop an Improved Intranasal Naloxone Formulation.....	19
1.	The volume of the nasal cavity naturally limits the volume of a naloxone nasal spray to about 100 µL per spray.	19
2.	A POSA would have been motivated to use a 4–6 mg naloxone dose to achieve desirable naloxone exposure levels.	20

3.	A POSA would have had adequate know-how and ability to select commonplace excipients to make a stable, well-tolerated intranasal naloxone formulation.....	21
4.	A POSA would have been motivated to load an intranasal naloxone formulation into an easy-to-use single-dose, pre-primed nasal sprayer.	24
VI.	CLAIM CONSTRUCTION UNDER 37 C.F.R. § 42.104(b)(3)	25
A.	“pre-primed”	25
B.	“patient”	26
C.	“wherein no more than about [x]% of the droplets have a diameter less than 10 μm,” “wherein the median droplet size is between about [x] μm and about [y] μm,” and “wherein approximately 90% of droplets have a diameter less than about 100 μm.”	26
D.	“wherein the patient experiences a geometric mean naloxone C _{max} ” and “wherein the patient experiences a plasma naloxone concentration such that the geometric mean of area under a plasma concentration versus time curve (AUC _{0-∞})”	27
E.	“bioavailable”	28
VII.	SUMMARY OF PRIOR ART	28
A.	Davies (PCT Patent Publication WO 00/62757).....	28
B.	Additional References	29
C.	Public Accessibility of the April 12, 2012 FDA Materials.....	30
D.	Zomig Review (Nalox1024) was Publicly Accessible	32
VIII.	THE CHALLENGED CLAIMS ARE UNPATENTABLE	32
A.	Ground 1: Claims 1–2 are obvious over Davies (Nalox1009) and HPE (Nalox1012).....	32
1.	Claim 1	32
2.	Claim 2	35
B.	Ground 2: Claims 3–5 are obvious over Davies (Nalox1009), HPE (Nalox1012), Bahal (Nalox1014), and Kushwaha (Nalox1013).....	35
1.	Claim 3	35
2.	Claim 4	39
3.	Claim 5	40

Petition for *Inter Partes* Review of U.S. Patent No. 9,561,177

C. Ground 3: Claims 6–8 are obvious over Davies (Nalox1009), HPE (Nalox1012), Bahal (Nalox1014), Kushwaha (Nalox1013), and Djupesland (Nalox1010).....	42
1. Claim 6	43
2. Claim 7	43
3. Claim 8	44
D. Ground 4: Claim 9 is obvious over Davies (Nalox1009), HPE (Nalox1012), Bahal (Nalox1014), Kushwaha (Nalox1013), and Wyse (Nalox1007).	44
E. Ground 5: Claims 10–11 are obvious over Davies (Nalox1009), HPE (Nalox1012) and Wyse (Nalox1007).	46
F. Ground 6: Claims 12–15 and 21 are obvious over Davies (Nalox1009), HPE (Nalox1012), Djupesland (Nalox1010), and the '291 patent (Nalox1015).	48
1. Claim 12	48
2. Claim 13	50
3. Claim 14	50
4. Claim 15	50
5. Claim 21	51
G. Ground 7: Claims 16–20, 22–23, and 29 are obvious over Davies (Nalox1009), HPE (Nalox1012), Djupesland (Nalox1010), the '291 patent (Nalox1015), and Wyse (Nalox1007).	52
1. Claim 16	52
2. Claim 17	53
3. Claim 18	54
4. Claim 19	55
5. Claim 20	55
6. Claim 22	56
7. Claim 23	57
8. Claim 29	57
H. Ground 8: Claims 24–27 are obvious over Davies (Nalox1009), HPE (Nalox1012), Djupesland (Nalox1010), Bahal (Nalox1014), Kushwaha (Nalox1013), the '291 patent (Nalox1015), and Wyse (Nalox1007).....	58

Petition for *Inter Partes* Review of U.S. Patent No. 9,561,177

I. Ground 9: Claim 28 is obvious over Davies (Nalox1009), HPE (Nalox1012), Djupesland (Nalox1010), the '291 patent (Nalox1015), and Wyse (Nalox1007), and optionally Wang (Nalox1008) and Pharmacologist POSA knowledge, or Wermeling 2013 (Nalox1016).....59

J. Ground 10: Claim 30 is obvious over Davies (Nalox1009), HPE (Nalox1012), Djupesland (Nalox1010), the '291 patent (Nalox1015), Wyse (Nalox1007), and Zomig Review (Nalox1024).....60

IX. SECONDARY CONSIDERATIONS62

 A. No teaching away62

 B. No commercial success65

 C. No long-felt but unmet need or failure of others.....66

 D. No unexpected superior results67

X. CONCLUSION68

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.